Company Overview - Merus N.V. is a biotechnology company specializing in innovative cancer therapies, particularly known for its bispecific antibody technology aimed at effectively targeting and destroying cancer cells [1] - The company competes with other biotech firms, notably Genmab A/S, which is currently involved in a significant transaction with Merus [1] Stock Performance and Price Target - On September 29, 2025, Wells Fargo set a price target of $97 for MRUS, indicating a potential increase of approximately 2.69% from its trading price of $94.46 at that time [2] - The agreed sale price of $97 per share in the ongoing acquisition by Genmab A/S aligns with this price target [2] Shareholder Investigation - Halper Sadeh LLC is investigating the fairness of the $97 sale price for Merus shareholders, assessing whether the company and its board have fulfilled their duties in this transaction [3] - The current stock price of MRUS is $94.12, reflecting a significant increase of 36.62% over the past year [3] Market Capitalization and Trading Activity - Merus has experienced a notable rise in stock price, with a fluctuation range between $94.06 and $94.55, marking the highest price over the past year, while the lowest was $33.19 [4] - The company's market capitalization is approximately $7.12 billion, indicating a substantial presence in the biotech sector [4] - Today's trading volume for MRUS is 14.86 million shares, suggesting strong investor interest [5]